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Summary 
 
Peripheral glucagon-like peptide-1 (GLP-1) is a hormone secreted by mucosal 
cells of the gut. It affects glucose metabolism and gastrointestinal functions, 
but has also been proposed to take part in the control of food intake. Exoge-
nous GLP-1 administration has been shown to decrease food intake under 
various conditions. However, the physiological site of action of intestinal GLP-
1 to reduce food intake is still unclear.   
 
We therefore performed studies in rats to investigate the effects of intraperito-
neal (IP) GLP-1 administrations on food intake and to identify the afferent sig-
nalling pathway and the brain areas involved. We found that 10, 30 and 90 
nmol/kg GLP-1 reduced meal size, but not in a clearly dose-related manner. 
As the eating-inhibitory effect of IP GLP-1 was attenuated by subdiaphrag-
matic vagal deafferentation, we conclude that vagal afferents are involved. To 
determine the brain regions activated by IP GLP-1, we applied c-Fos immu-
nohistochemistry and found neuronal activation in the caudomedial part of the 
nucleus tractus solitarii (NTS) and in the caudal part of the central nucleus of 
the amygdala (CeA). The NTS activation by GLP-1 supports a role of vagal 
afferents in the mediation of GLP-1’s satiating effect. Whether the CeA activa-
tion reflects satiation or aversion remains to be identified.   
 
To better understand the signalling pathways and to clarify the physiological 
relevance of peripheral GLP-1 in satiation, however, further investigations are 
required.  
Zusammenfassung 
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Zusammenfassung 
 
Peripheres Glucagon-like peptide-1 (GLP-1) wird von Mucosazellen des Dar-
mes sezerniert. Es beeinflusst den Glucosestoffwechsel und gastrointestinale 
Funktionen, soll aber auch zur Steuerung des Verzehrs beitragen. Die paren-
terale Verabreichung von GLP-1 reduziert den Verzehr unter verschiedenen 
Bedingungen. Der physiologische Wirkungsort von intestinalem GLP-1 ist bis-
her jedoch unbekannt.  
 
Wir führten Studien an Ratten durch, um die Effekte von intraperitoneal (IP) 
appliziertem GLP-1 auf den Verzehr zu untersuchen und die involvierten affe-
renten Signalwege und Hirnareale zu identifizieren. Dabei reduzierten 10, 30 
und 90 nmol/kg GLP-1 die Mahlzeitengrösse, ohne dass eine klare Dosisab-
hängigkeit dieses Effekts feststellbar war. Da der verzehrshemmende Effekt 
von IP infundiertem GLP-1 nach subdiaphragmatischer vagaler Deafferentati-
on abgeschwächt war, sind offenbar vagale Afferenzen involviert. Mit c-Fos 
Immunohistochemie fanden wir, dass IP appliziertes GLP-1 Neuronen im cau-
domedialen Teil des Nucleus tractus solitarii (NTS) und im caudalen Teil des 
zentralen Nucleus der Amygdala (CeA) aktiviert. Die NTS-Aktivierung durch 
GLP-1 spricht ebenfalls für eine Rolle der vagalen Afferenzen bei der Vermitt-
lung des Sättigungseffekts. Ob die CeA-Aktivierung Sättigung oder Übelkeit 
widerspiegelt, bleibt zu untersuchen. 
 
Um die Signalwege besser zu verstehen und die physiologische Relevanz von 
peripherem GLP-1 für die Sättigung zu klären, sind weitere Studien nötig. 
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1. Introduction 
 
1.1. Control of food intake 
Body weight (BW) of most animals remains stable over time, although energy 
intake and expenditure can vary substantially. This stability of BW is based on 
a complex system of intertwined physiological mechanisms controlling food 
intake and energy expenditure, but the available evidence indicates that con-
trolling food intake is more important than controlling energy expenditure for 
energy homeostasis. The central nervous system controls food intake by inte-
grating orosensory signals (flavour, palatability), gut signals (various peptides, 
gastric distension), metabolic signals (mainly glucose and fatty acids or their 
metabolization) and putative adiposity signals (leptin, insulin and amylin). The 
latter signals modulate the effect of short-term satiation signals (1), and their 
plasma levels are supposed to reflect the size of fat stores (2;3). 
Among the different gut peptides that contribute to the control of food intake 
and, hence, the maintenance of energy balance, ghrelin is the only orexigenic 
(i.e., eating-stimulatory) hormone. It is synthesized and secreted by X-cells in 
the stomach during fasting and powerfully stimulates food intake (4). 
The probably best studied gut peptide and prototype of an endocrine satiation 
signal is cholecystokinin (CCK), which is released by I-cells of the duodenal 
and jejunal mucosa (5) in response to meals. Proteins and long-chain fatty ac-
ids are the most potent nutrient stimuli of CCK release (6). In a paracrine way 
of action CCK activates receptors on vagal afferents originating within the 
lamina propria mucosae and the muscle layers of the gastrointestinal wall 
(7;8). These afferents project to the nucleus tractus solitarii (NTS) in the hind-
brain (9;10). Vagotomy blocks (11), and lesions of the majority of the NTS and 
the area postrema (AP) significantly attenuate (10) the satiation effect of CCK, 
supporting the role of vagal afferents in the signalling pathway of CCK. Fur-
ther evidence for a paracrine rather than endocrine satiation effect of CCK 
comes from studies showing that exogenous CCK reduced food intake less 
efficiently after intraportal than after intraperitoneal (IP) administration (12) or 
not at all after intraportal injection (13). In the NTS, CCK-triggered afferent 
signals are mediated by melanocortin-4 receptors (14) and further relayed to 
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other brain areas including the hypothalamus. Also, the CCK signals are inte-
grated with other input such as adiposity signals or social factors (15). Main 
effects of CCK in addition to the inhibition of eating (16;17) include a short-
term inhibition of gastric emptying (18) and acid secretion (19), a stimulation 
of the exocrine pancreas (20) and gallbladder contraction (6). 
In 1973 Gibbs, Young and Smith showed that peripheral administration of ex-
ogenous CCK leads to a short-term, dose-related reduction of food intake in 
rats (16). They established the concept of humoral factors derived from the 
gastrointestinal tract (GIT) as important signals in the control of food intake 
and proposed that CCK met the following criteria for physiological relevance 
of a satiation signal: 1) activation of the signal as a consequence of eating, 2) 
decrease of meal size after exogenous administration, 3) rapid onset and brief 
duration of the effect, and 4) inhibition of eating not due to illness. Later these 
criteria were slightly modified and some additional aspects added: 5) admini-
stration of a selective and potent antagonist should neutralize the effect of the 
endogenous hormone and the effect of exogenous hormone administered in 
physiological doses, and 6) receptors for the molecule should be found at the 
site of action. Finally, 7) removal of the hormone or its receptors should pre-
vent the eating effect and replacement of the hormone at physiological doses 
should normalize it (21;22). 
 
1.2. Glucagon-like peptide-1 – general aspects 
In the 1960s it was discovered that in response to glucose other substances 
are released in addition to insulin and that these substances are chemically 
similar to glucagon. They were therefore named “glucagon-like”, and one of 
them was later described as glucagon-like peptide-1 (GLP-1) (23;24). GLP-1 
belongs to a group of peptides which are all derived from the pre-pro-
glucagon gene. This gene also codes for glucagon, oxyntomodulin, glicentin-
related pancreatic polypeptide and GLP-2 (25). The tissue-specific posttrans-
lational processing determines which peptide(s) are finally produced (26). 
In the brain, GLP-1 is expressed in central and caudal parts of the NTS (27-
30) from where these GLP-1 neurons project to the hypothalamus (including 
the arcuate (Arc) and paraventricular (PVN) nuclei), thalamus, pituitary, cen-
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tral nucleus of the amygdala (CeA) and dorsovagal complex (29;30). The 
GLP-1 receptors in the different brain areas, i.e. hypothalamus and brainstem 
(31-33), may be reached by central as well as peripheral GLP-1. Peripheral 
GLP-1 may get into the brain through circumventricular organs (CVO). It has 
been shown that GLP-1 as well as its receptor-agonist exendin-4 (Ex4) can 
cross the blood brain barrier (BBB) (34-36). However, it should be considered 
that GLP-1 has a very short half-life in blood (see below). Furthermore, a 
study using the GLP-1 albumin fusion protein Albugon, which does not cross 
the BBB, showed that this protein injected IP enhanced insulin secretion, re-
duced food intake and blood glucose and activated c-fos expression in differ-
ent brain areas. This suggests that activation of centrally mediated mecha-
nisms by peripheral GLP-1 does not require direct exposure of central nerv-
ous system (CNS) GLP-1 receptors to GLP-1, but could also be induced indi-
rectly by another mediator (37). 
In the periphery GLP-1 is produced by mucosal L-cells, which are primarily 
found in the ileum, but also in other parts of the small and large intestines 
(38;39). In these endocrine cells GLP-1 is colocalized with glucose-dependent 
insulinotropic polypeptide (= gastric inhibitory polypeptide = GIP) or peptide 
YY (PYY) (40). In the periphery, receptors for GLP-1 are found in pancreatic 
islets, stomach, intestines, nodose ganglion neurons of the vagus nerve, lung, 
heart and kidneys (31-33;41). 
The release of intestinal GLP-1 is stimulated by direct contact of nutrients with 
the mucosa (42;43). Especially fatty acids, but also carbohydrates, are potent 
stimuli of GLP-1 secretion. In response to meals, GLP-1 is released in a bi-
phasic pattern with an early peak that is presumably due to carbohydrates and 
a second peak that is mainly triggered by fat (44). Carbohydrates strongly 
stimulate GLP-1 release consistent with their role in glucose metabolism. 
However, differences in the GLP-1 response after consumption of different 
types of carbohydrates were reported. After equivalent amounts of glucose or 
complex carbohydrates only glucose test meals increased GLP-1 levels (45). 
Fat leads to a delayed and longer lasting rise of circulating GLP-1 levels com-
pared to carbohydrates (45-48). Long-chain fatty acids generated by fat hy-
drolysis seem to play an important role in fat-stimulated GLP-1 release in hu-
mans (48). Increasing amounts of lipid calories stimulated GLP-1 release into 
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the lymph dose-dependently in rats (49). The role of proteins in GLP-1 release 
is controversial. In some human studies high protein meals led to even higher 
GLP-1 levels than meals rich in carbohydrates (50;51). Another study reported 
no effect of protein meals on GLP-1 secretion at all (45). 
The secretion of GLP-1 is further regulated by neural signals. In particular the 
vagal muscarinic and the sympathetic nervous systems have been proposed 
to be involved (42). Also hormones contribute to the regulation of GLP-1 re-
lease. GIP for instance has been shown to stimulate GLP-1 secretion in rats 
(42;52), and a recent study in humans reports that GLP-1 secretion is also 
mediated by CCK release and CCK-1 receptors (48). These upper small intes-
tinal peptides may contribute in particular to the early phase of GLP-1 release 
during a meal. 
 
1.3. Effects of GLP-1 
The main physiological effects of GLP-1 are presumably on glucose metabo-
lism and GIT function, whereas its impacts on the cardiovascular system (53) 
or on neuroprotection and learning (54) appear to be physiologically less im-
portant. 
GLP-1, together with GIP, contributes to the so-called incretin effect, i.e., to 
the amplification of insulin secretion elicited by hormones secreted from the 
GIT. Thus, the same amount of glucose produce much higher insulin levels 
after oral than after intravenous (IV) administration (38;55-57). In addition, 
GLP-1 has trophic effects on the pancreatic beta cells, i.e., it stimulates their 
proliferation and enhances their differentiation (58), and it inhibits beta cell 
apoptosis (59). Furthermore, GLP-1 inhibits glucagon secretion, which leads 
to a decrease in hepatic gluconeogenesis (60), and it increases somatostatin 
secretion (61). 
In the GIT GLP-1 inhibits secretion (62) and motility (63). The inhibitory effect 
on gastric emptying has been shown to depend on intact vagal afferents (64). 
Together with PYY GLP-1 acts as a mediator of the ileal brake, i.e., the endo-
crine inhibition of upper gastrointestinal functions elicited by the presence of 
unabsorbed nutrients in the ileum (65).  Finally, GLP-1 as well as its receptor 
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agonist Ex4 have been shown to reduce food intake under different condi-
tions. 
Because of its beneficial effects on glucose metabolism and food intake, GLP-
1 is an interesting peptide for the therapy of adiposity and type II diabetes. In-
deed, incretin-based therapies enhance endogenous insulin secretion without 
causing hypoglycaemia or weight gain. However, GLP-1 itself is not suitable 
as a drug because of its rapid degradation by the enzyme dipeptidyl peptidase 
IV (DPP-IV). Therefore, two main classes of pharmaceuticals that are avail-
able currently attract attention: GLP-1 receptor agonists (e.g. Exenatide, 
Liraglutide) and DPP-IV inhibitors (e.g. Sitagliptin, Vildagliptin) (66). 
 
Intracerebroventricular (ICV) injection of GLP-1 or Ex4 acutely reduced food 
and water intake in rats, and also caused a decrease in BW when adminis-
tered repetitively (67-71). In turn, ICV administration of the GLP-1 receptor an-
tagonist exendin (9-39) (Ex9) stimulated eating and increased BW, supporting 
a physiological central effect of GLP-1 receptor activation in the control of eat-
ing (67;68). Interestingly, different effects of GLP-1 seem to be integrated by 
different hypothalamic nuclei, i.e., the central effect of GLP-1 on glucose me-
tabolism seems to be mediated by GLP-1 receptors in the Arc, while the PVN 
seems to be responsible for GLP-1’s satiation effect (72). 
Also peripheral IV administration of GLP-1 generally reduced food intake in 
man and animals (73-76), and this effect seems to be independent from an 
inhibition of gastric emptying (73). IV administration of a long-acting GLP-1 
derivative induced weight loss in addition to reduced food intake (77). IP ad-
ministered GLP-1 and Ex4 also decreased food intake, although the pertinent 
reports are somewhat inconsistent concerning the effective doses. While 
some authors report that 0.3 – 30 nmol/kg GLP-1 administered IP had no ef-
fect on food intake (78;79), others found 10 – 100 nmol/kg to be effective 
(76;79-82). Although different routes of peripheral GLP-1/Ex4 administration 
(IV, IP as well as subcutaneous (SC) or intramuscular (IM) (71;83)) lead to a 
reduction in food intake, the involved mechanisms and sites of action seem to 
be different: thus, the eating-inhibitory effect of IP administered GLP-1 seems 
to depend on intact vagal afferents (82), whereas the effect of IV infused GLP-
1 does not (76). 
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These differences raise the questions of 1) which route of GLP-1 administra-
tion is most likely to mimic the physiological way and mode of action and 2) 
whether peripheral GLP-1 is physiologically relevant for the control of food in-
take at all. GLP-1 released from intestinal L-cells is collected by lymph vessels 
or by intestinal capillaries and transported to the hepatic portal vein (HPV) 
(84;85). The enzyme DPP-IV, which is expressed in capillary endothelial cells, 
immediately degrades GLP-1 (85;86), so that only about 25% of the released 
GLP-1 reaches the liver and only about 10-15% the systemic circulation (87). 
The biological half-life of endogenous GLP-1 in blood is therefore only 1-2 min 
(88). GLP-1 infused into the HPV or into the vena cava (VC) reduced meal 
size similarly, and intrajugular administration of GLP-1 reduced food intake 
even more potently than infusion into the HPV, arguing against the hepatic 
portal area or the liver as a site of action where peripheral GLP-1 inhibits eat-
ing (75;76). GLP-1 blood concentrations after a meal were significantly higher 
in the HPV than in the VC; more specifically, no systemic increase of circulat-
ing endogenous GLP-1 during a normal meal was measured in rats.  This 
questions a role of circulating GLP-1 as an endocrine satiation signal and 
suggests little physiological relevance of the satiating effect of IV administered 
GLP-1 (Rüttimann et al., in review). 
Unlike IV administered GLP-1, IP administered GLP-1 may act on intestinal 
vagal afferents and therefore mimic a paracrine action of endogenous GLP-1, 
similar to CCK’s supposed action after IP injection (8). However, IP GLP-1 
could of course also enter the blood stream by being absorbed into superficial 
capillaries of the intestines or of other abdominal organs. 
All in all, a physiological role of peripheral endogenous GLP-1 in satiation is 
presently questionable. This fits the inconsistent effects of peripheral GLP-1 
receptor antagonism on food intake: Whereas Williams et al. demonstrated 
that IP injection of the GLP-1 receptor antagonist Ex9 increased food intake 
under certain conditions (81), Rüttimann et al. failed to replicate this finding 
under slightly different conditions designed to mimic what happens during a 
normal meal (89). In addition to the inconsistent effects of GLP-1 receptor an-
tagonism, the presence of GLP-1 receptors does not appear to be crucial for 
energy homeostasis. Thus, GLP-1 receptor knockout mice do not become 
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obese, but they are glucose intolerant, supporting a crucial role of GLP-1 in 
glycaemia regulation rather than energy homeostasis (90). 
 
1.4. C-Fos 
A common method to assess neuronal activation is c-Fos immunohistochem-
isty (IHC). C-fos is an immediate-early gene, which means that it is tran-
scribed within few minutes after activation (91). Activation is induced by many 
different, non-specific stimuli. For instance, c-fos is expressed in neurons in 
response to direct stimulation by growth factors and neurotransmitters and 
therefore maps functional pathways (92). In addition to IHC, in situ hybridisa-
tion is also suitable to examine the expression of this gene, and different kinds 
of double-labelling studies can be performed (93). 
Brain activation patterns after food intake and in relation to physiological satia-
tion have been studied by c-Fos IHC, and it seems that large meals induce c-
fos expression in the NTS, in particular in the medial part, and in the AP 
(94;95), whereas smaller meals induce c-fos expression in the NTS, PVN and 
CeA, but not in the AP (96-99). The number of c-Fos positive cells in the NTS 
was positively correlated with the amount of food consumed (98). Interest-
ingly, not only food intake, but also intense starving leads to an expression of 
c-fos in the brain. After 22 h food deprivation the dorsal motor nucleus of the 
vagus (DMX) was activated and the number of c-Fos positive cells increased 
compared to the control group (1h food deprivation) (99). 
Brain activation in rats after GLP-1 administration via different routes has also 
been investigated by c-Fos IHC. After ICV application of GLP-1 an induction 
of c-fos expression was reported in the NTS, AP, Arc, PVN, CeA, lateral 
parabrachial nucleus, supraoptic nucleus and bed nucleus of the stria termi-
nalis, but not in the anterior CVO (100). The effect of GLP-1 on the PVN and 
CeA was inhibited by prior ICV Ex9 administration (68). 
A recent study from our laboratory reported increased c-fos expression in the 
NTS, AP and CeA, but not in the hypothalamus (PVN and Arc) following HPV 
infusion of GLP-1 (101). In another study, femoral vein infusion of Ex4 also 
activated the NTS and AP and also the PVN, as well as the external lateral 
subdivision of the parabrachial nucleus and the rostral ventrolateral medulla 
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(102). In contrast, comparatively low doses of IP injected GLP-1 (7.6 and 10 
nmol/kg respectively) did not induce c-fos expression in the brainstem (NTS, 
AP) or in the hypothalamus (Arc, PVN) (100;103). A much higher GLP-1 dose 
of 100 nmol/kg injected IP yielded c-Fos positive cells in the Arc, which was 
the only brain area examined for c-Fos in that study (82). In mice, which ap-
pear to be generally less sensitive to GLP-1 administration, the same GLP-1 
dose (100 nmol/kg) led to c-fos expression in the NTS, Arc and PVN (104). In 
contrast, another study in mice failed to detect any c-Fos positive cells in 
these and other brain regions after IP injection of 900 nmol/kg GLP-1 (105). 
 
1.5. Aim of the thesis 
The mechanisms of the eating-inhibitory effect of peripherally administered 
GLP-1 are still unclear. In particular, further research is needed to determine 
where and how peripherally applied GLP-1 acts to reduce food intake and to 
specify the role of the vagus in this effect. The aim of this study was therefore 
to first revisit the question of whether the eating-inhibitory effect of IP adminis-
tered GLP-1 depends on intact abdominal vagal afferents, using the model of 
subdiaphragmatic vagal deafferentation (SDA) in rats. We tried to mimic the 
physiological condition as accurately as possible and therefore performed 
meal-contingent remotely controlled infusions instead of injections and used a 
moderate IP dose of 10 nmol/kg GLP-1, which was previously found to reduce 
food intake in sham-operated but not in SDA rats (76). In this study, however, 
relatively few animals were used under specific conditions, i.e., that every rat 
was not only equipped with an IP, but also with a HPV catheter. Thus we con-
sidered it appropriate trying to replicate these findings. In a second experi-
ment we investigated the effect of different doses of meal-contingent, IP infu-
sions of GLP-1 (10, 30, 90 nmol/kg) on food intake to examine whether the 
eating-inhibitory effect is dose-related. 
 
After establishing a moderate dose of GLP-1 that reliably decreased food in-
take after IP infusion, we then used this dose (30nmol/kg) to perform a second 
experiment in which we focused on c-fos expression in different brain areas 
(NTS, AP, PVN, Arc and CeA). Currently there are only few reports about 
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neuronal activation patterns after IP administration of GLP-1 in rats. In particu-
lar, complete studies of c-fos expression in brainstem and hypothalamus re-
gions, after IP administration of GLP-1 are missing. Additionally it would be of 
value to investigate this issue with a dose of GLP-1 that had a reliable effect 
on food intake. Furthermore, it would be interesting to directly compare c-fos 
expression after IP and IV applied GLP-1, regarding the different routes and 
mechanisms of peripheral administered GLP-1 discussed. 
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2. Material and Methods 
 
2.1. Subjects and housing 
Male Sprague Dawley (Crl:®CD) rats (mean BW 170 g on arrival) were pur-
chased from Charles River Laboratories (Sulzfeld, Germany) and housed in 
climate-controlled rooms (23±2 °C, 45 % humidity). The rats were kept on a 
12/12 h light/dark cycle and a radio tuned into a local radio station was played 
for 24 h/day in order to mask extraneous noises. Standard ground rat chow 
(No 3433, Provimi Kliba AG, Kaiseraugst, Switzerland) for the behaviour ex-
periments and pellets (No 3436,) for the c-Fos study as well as tap water was 
available ad libitum except when otherwise noted. Rats were adapted to hous-
ing conditions for at least 10 d before experiments began. All procedures were 
approved by the Veterinary Office of the Canton of Zurich. 
 
2.2. Surgeries 
Ten to 14 d after arrival, rats were equipped with chronic IP catheters, as de-
scribed previously (76). For the custom-made catheters 20 G needles (0.9 x 
40 mm; Sterican®, B. Braun, Melsungen, Germany) were bilaterally polished 
and bent into L-shaped “neck pieces”. Twenty-two cm long silastic tubing (ID: 
0.508 mm, OD: 0.9398 mm; Gore, W.L., Newark, DE, USA) were connected 
to the neck pieces and junctions were shielded with additional 1.5 cm long 
tubing (ID: 0.762 mm, OD: 1.651 mm). The neck pieces were then led through 
2 x 3 cm pieces of monofilament knitted polypropylene mesh (Bard®Mesh; 
Bard Davol, Warwick, RI, USA) and fixed to the mesh with non-absorbable 
sutures (Braunamid®; B. Braun). Small (∅ 1-2 mm) silicon bubbles (Silicone 
Rubber Adhesive RTV 108; Momentive Performance Materials, Albany, NY, 
USA) were placed on the silastic tubing 1cm from the distal end that remained 
in the abdominal cavity, to ease the fixation to the abdominal wall. Small holes 
were punched into the last cm of the catheter with a 26 G needle.  Before im-
plantation catheters were soaked in a disinfectant solution (Kodan® Tinktur 
Forte; Schülke & Mayr GmbH, Norderstedt, Germany) for at least 30 min, and 
then carefully rinsed with sterile 0.9% saline (B. Braun). 
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In experiment 1 (Exp1), rats received SC injections of 4 mg/kg trimethoprim/ 
20 mg/kg sulfadoxin (Borgal 24%; Intervet, Shering-Plough Animal Health, 
Kenilworth, NJ, USA), 0.05 mg/kg atropine (Atropinum Sulf.; Sintetica S.A., 
Mendrisio, Switzerland) and 25 µg/kg buprenorphine (Temgesic®; Reckitt 
Benckiser Healthcare (UK) Ltd. ) prior to surgery. Anaesthesia was induced by 
5% isoflurane (Attane, Minrad Inc., Buffalo, NY, USA) in oxygen and main-
tained with 1.5-3% isoflurane in 1:1 oxygen/dinitrogenoxide. In experiment 2 
(Exp2), animals were pretreated again with the same doses of 
trimethoprine/sulfadoxine and atropine SC and anaesthesia was induced by 
IP injection of 80 mg/kg ketamine (Narketan®10; Vétoquinol AG, Ittingen, 
Switzerland) and 4 mg/kg xylazine (Rompun 2%; Bayer Health Care, 
Leverkusen, Germany). 
From a 2 cm long interscapular midline-incision the L-shaped neck piece was 
advanced SC 1 cm cranially and exteriorized through a puncture hole in the 
skin. The silastic tube was guided SC from the neck to a midline laparotomy 
and inserted into the abdomen through a stab incision 1 cm besides the mid-
line. The end of the catheter was fixed on the serosa of the right abdominal 
wall with silk sutures (4-0 Perma-Handseide; Ethicon, Norderstedt, Germany) 
(76). 
Muscles and skin were closed with resorbable sutures (3-0 and 5-0 Vicryl, 
Ethicon) for the muscle layer and for the SC and cutaneous sutures, respec-
tively. Five mg/kg carprofen (Rimadyl®; Pfizer AG, Zürich) was administered 
SC immediately after surgery and for 3 (Exp1) or 2 (Exp2) d thereafter. Four 
mg/kg trimethoprine and 20 mg/kg sulfadoxin were given SC on the day after 
surgery. 
Catheters were flushed daily with 1 ml sterile 0.9 % saline for the first week 
after surgery, later on they were flushed every 2nd or 3rd day. 
 
In addition to the IP catheter implantation, in Exp1 SDA surgery (n=19) was 
performed as previously described. The left dorsal vagal rootlets and dorsal 
(left) esophageal vagal trunks were cut under a microscope, which results in 
complete SDA, while approximately half of the abdominal vagal efferents are 
left intact (106). For the sham procedure animals (n=14) underwent similar 
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exposure of the vagal rootlets and abdominal vagus, but without further ma-
nipulation. 
 
2.3. SDA verification 
SDA were verified functionally and histologically. The functional test was the 
loss of a reduction in food intake after IP administration of CCK, an effect 
which is known to depend on abdominal vagal afferents (107;108). For this 
test the same setup as in the behavioural studies (see below) was used. After 
12 h of food deprivation animals were attached to the extension tubes of their 
catheters and connected to the infusion pumps 1 h prior to dark onset (76).  At 
dark onset rats received free access to food and 1.5 min after their individual 
meal onset they received an IP infusion (0.2 ml/min) of 4 µg/kg CCK-8 
(Bachem, Bubendorf, Switzerland) dissolved in 0.5 ml phosphate-buffered sa-
line (PBS; Gibco, Basel, Switzerland) with 1% bovine serum albumin (BSA; 
Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) or vehicle (PBS with 1% 
BSA) according to a crossover design. SDA rats that showed a > 30% reduc-
tion of 30 min cumulative food intake (CFI) after CCK treatment were ex-
cluded from the analysis. 
The histological test was retrograde labelling of vagal motor neurons in the 
DMX (109;110). For analgesia rats were pre-treated with 75 µg/kg buprenor-
phine  and 30-60 min later they were infused through the IP catheter with 2 
mg fluorogold (Fluorochrome, Denver, CO, USA) diluted in 1 ml saline.  Then 
the catheters were flushed with 1 ml saline. Four d later the rats were deeply 
anesthetised with 100 mg/kg sodium pentobarbital (Cantonal Pharmacy, Zu-
rich, Switzerland) IP, transcardially perfused with PBS (0.1 M) and 4% para-
formaldehyde (PFA; Electron Microscopy Sciences, Hatfield, PA, USA). 
Brains were removed, postfixed overnight in 4% PFA, moved into 30% su-
crose (Merck, Zug, Switzerland) in 0.1 M PBS and stored at 4°C until further 
processing. Under light protection brainstems were sliced on a freezing sliding 
microtome (Microm International, Walldorf, Germany) and sections (40 µm) 
mounted on gelatine coated slides and dried. Fluorogold-labeled neurons in 
the DMX in all sections that included the AP were counted by an experimenter 
blind to the surgical group and behavioural data. The inclusion criteria for SDA 
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rats were that the number of labelled cells in the right DMX was ≤ 3 % of the 
number in the left DMX and that the left DMX contained some retrograde la-
belling as positive control. Only the 10 SDA rats that met the criteria for func-
tional and histological verification were included in the analysis. 
 
2.4. IP catheter verification 
To verify the position and integrity of the IP catheters, the animals (only Exp2) 
were scanned by computed tomography (CT) using a Micro CT LaThetaTM CT 
scanner (Aloka Co. Ltd. Japan). Rats were food-deprived for 1-3 h and anes-
thetized with 2-3% isoflurane in oxygen. An Iohexol containing (300 mg/ml) 
contrast agent (Accupaque®; Amersham Health AG, Wädenswil, Switzerland) 
was diluted in 0.9% saline (2 parts Accupaque® and 1 part saline) immedi-
ately prior to use. 0.6 ml of this mixture was infused into the catheter and 30-
60 sec later rats were scanned. Animals showing SC catheter leakage or IP 
pouches filled with contrast agent (instead of diffusely distributed contrast 
agent in the whole abdominal cavity), were excluded. 
 
Furthermore in all animals the position and intactness of the IP catheters was 
visually verified post mortem. 
 
2.5. Behavioural experiments 
After at least 10 d recovery from surgery, animals were individually housed in 
acrylic infusion cages (37 x 21 x 41 cm, l x w x h) with stainless-steel grid 
floors. Chow was accessible through a niche (5 x 7 x 30 cm, 6 cm above the 
cage floor).  The food cups were fixed on electronic balances (X S4001S, Met-
tler-Toledo, Greifensee, Switzerland), which were interfaced with a PC. Meal 
patterns were recorded and analyzed by a computer program (LabX-Meal-
analyzer 1.4., Mettler Toledo).  In addition, the rats’ behaviours were moni-
tored by infrared video cameras (Conrad Electronic GmbH, Hirschau, Ger-
many).  Infusions were given by remotely controlled pumps (Multiple Speed 
Syringe Pump, R99-E, Razel® Scientific Instruments, St. Albans, VT, USA) 
(101).  
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Exp1: 
Rats (n=14, BW=507g ±25g) were adapted to all experimental procedures for 
at least 7 d. At light onset, the access to food was blocked and 1 h before dark 
onset the IP catheters were attached to the infusion pumps as described pre-
viously (76). The rats’ neck pieces were connected to polyethylene tubing (ID: 
0.76 mm, OD: 1.22 mm, BPE-T60; Instech Laboratories, Plymouth Meeting, 
PA, USA) consisting of two parts. The part between the rat and a swivel joint 
(375/20PS; Instech Laboratories), which was fixed to the cage with a 
stainless-steel expander spring, was 50 cm long and shielded with a stainless-
steel spring. The part between swivel and syringe was 90 cm long. This con-
struction allowed the rats to move freely in their cages. 
At dark onset the rats received access to fresh food, and 1.5 min after the on-
set of  their first nocturnal meal IP infusions (0.2 ml/min, 2.5 min) of 10 
nmol/kg GLP-1 (7-36; Bachem) dissolved in PBS with 1% BSA or vehicle 
(PBS with 1% BSA) were administered.  Four hours after dark onset catheters 
were detached from the infusion pumps and flushed with saline. A within-
subject crossover design was used, and animals were distributed to body-
weight matched groups and tested on consecutive days. 
 
Exp2: 
For the 2nd experiment the same setup was used as in Exp1. Rats (n = 16, 
BW = 414 g ± 24 g) received GLP-1 (7-36) doses of 10, 30 or 90 nmol/kg BW 
or vehicle. A within-subject crossover design was used and infusions were 
given in random order on consecutive days. 
 
2.6. Terminal experiment for c-Fos immunohistochemistry  
For the c-fos study rats (n = 15, BW = 306 g ± 14 g) were adapted to 15 h 
food deprivation (starting at light onset) and the IP injection procedures for 3 
d. On the day of the terminal experiment animals received an IP injection of 
30 nmol/kg GLP-1 (7-36; Bachem) dissolved in 0.5 ml PBS with 1 % BSA or 
0.5 ml vehicle (PBS with 1 % BSA) at dark onset. Ninety min later rats were 
deeply anesthetised with 83 mg/kg sodium pentobarbital IP, and transcardially 
perfused with PBS (0.1 M, 30-40 ml/min) and 4 °C cold 4% PFA (Electron Mi-
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croscopy Sciences, Hatfield, PA, USA). The experiment was performed on 
two consecutive days, and animals were perfused at 6 min intervals. Brains 
were removed, postfixed in 30 ml 4% PFA for 1 h, moved into 10 % sucrose 
solution overnight (12h) and then placed into 30 % sucrose for 24-72 h. Finally 
the brains were snap-frozen in powder-dry ice and stored at -60 °C in an air-
tight container until further processing. 
 
2.7. C-Fos immunohistochemistry 
Brains were sliced using a freezing sliding microtome. Sections of 40 µm 
thickness were collected and stored in a cryoprotectant solution (40 % 50 mM 
phosphate buffer, 30 % glycerol and 30 % ethylene glycol; Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland) at -20 °C until staining. For the c-Fos IHC 
sections were rinsed in 0.1 M PBS for 3 x 5 min and quenched in 0.1 M PBS 
containing 0.5 % peroxidase (H2O2, 30 %, Sigma-Aldrich) for 30 min. After 
another washing step, sections were blocked in 5 % normal goat serum (NGS; 
Sigma-Aldrich) in 0.1 M PBS with 0.3 % Triton-X (= 0.3 % PBTx; Sigma-
Aldrich) for 1 h and then incubated with the primary antibody (1:2500, rabbit 
polyclonal anti-c-Fos, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; in 
2 % NGS in 0.3 % PBTx) overnight (12h) at room temperature (RT). Sections 
were rinsed again and then incubated with a secondary biotinylated antibody 
(1:200, goat anti-rabbit IgG, Vector Laboratories, Burlingame, CA, USA; in 2 
% NGS in 0.3 % PBTx) for 1 h at RT. After another washing step with 0.1 M 
PBS, sections were incubated with Avidin DH and biotinylated horseradish 
peroxidase H (Vectostain ABC kit, Vector Laboratories) in 0.3 % PBTx for 1 h. 
Then sections were rinsed in 0.1 M Tris-buffer (Trizma® base, Sigma-Aldrich) 
and finally stained with 1.25 % 3,3’- Diaminobenzidinehydrochloride (40 mg/ml 
milipore water, Sigma-Aldrich) in 0.1 M Tris-buffer with 0.08 % H2O2 (30 %). 
Sections were mounted on gelatinised microscopy slides, dehydrated in an 
increasing alcohol row, defatted in xylene and cover slipped with DPX Mount-
ant (Sigma-Aldrich). 
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2.8. Taking pictures, counting 
To quantify the number of c-fos expressing cells, photographs of the regions 
of interest (ROI) were taken using a light-optical microscope (20 x magnifica-
tion; Olympus AX-70, Center Valley, PA, USA), which was connected to a 
digital colour camera (Retiga, QImaging, Surrey, BC, Canada) interfaced with 
a computer. Then the closest anterior-posterior bregma level according to a 
rat brain atlas (111) was assigned for each photograph and the ROI was 
manually charted on the computer screen using transparencies made from the 
brain atlas. Within these defined ROI c-Fos positive cells were counted manu-
ally by an observer blind to the treatments using the counting-particles-
function of Volocity 4 software (Improvision, Coventry, England). Brain regions 
counted were: NTS (13.5, 14.0 and 14.5 mm posterior to bregma), AP (1-2 
section at 14.0 and 14.2 mm posterior), PVN (1.2, 1.4, 1.6, 1.8, 2.0 mm poste-
rior), Arc (2.0, 2.2, 2.4, 2.6, 2.8 and 3.0 mm posterior), and CeA (1.6, 1.8, 2.0, 
2.2, 2.4, 2.6, 2.8, 3.0 mm posterior). For each bregma level values of the left 
and the right side of NTS, PVN, Arc or CeA were added. 
One animal had to be excluded from analysis of AP and NTS c-Fos because 
the background of the IHC staining was extremely dark and reliable counting 
therefore impossible. Furthermore, for some animals different levels were 
missing. 
 
2.9. Data analysis 
All analyses were done using SPSS computer program (17.0 SPSS Inc., Chi-
cago, IL, USA). Differences were considered significant when p < 0.05. 
 
Behavioural experiments 
Meals were defined as ≥ 0.3 g decreases of the food cup weights and visual 
confirmation of eating on the video screen, with ≤ 15 min intervals between 
food removals. Animals that did not eat within the first 90 min after dark onset 
were excluded. 
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Exp1: 
To reduce the influence of extreme values, data were screened for outliers by 
converting data to standard scores using the medians and median absolute 
deviations x 1.48 (which estimates the standard deviation), and values > 2.57 
(p < 0.01) were excluded (112). As not all data sets met the criteria for nor-
mality and homogeneity of variance, first meal sizes (FMS) after GLP-1 and 
vehicle administration were compared separately for SDA and sham rats us-
ing a paired-sample t-test. Then the difference in FMS after GLP-1 and vehi-
cle (delta) was calculated for each animal and these deltas of the SDA ani-
mals were compared to those of the sham animals using an independent-
sample t-test. The same approach was used to analyze first meal duration 
(FMD). 
 
Exp2: 
FMS, FMD and CFI were analyzed using Repeated-Measures ANOVA and 
subsequent Bonferroni-Holm (113) planned comparisons were performed for 
the differences between single doses. Data sets which were not normally dis-
tributed were transformed into square roots and again extreme values were 
excluded. 
 
C-Fos experiment 
Since several sections of some bregma levels were missing, an average of 
counts of 2-3 adjacent sections was calculated for the AP and the forebrain 
structures. The following brain structures were analysed: NTS: 13.5, 14.0 and 
14.5 mm posterior to bregma, AP (14.0-14.2 mm posterior), PVN rostral (1.2-
1.4 mm posterior), PVN caudal (1.6-2.0 mm posterior), Arc rostral (2.2-2.4 mm 
posterior), Arc caudal (2.6-3.0 mm posterior), CeA rostral (1.6-2.0 mm poste-
rior), and CeA caudal (2.6-3.0 mm posterior). Again an outlier test was applied 
to identify extreme values and exclude them. C-Fos positive cell counts of 
GLP-1 and vehicle treated rats were analyzed with an independent-sample t-
test for each bregma level and brain region respectively. 
Results 
22 
3. Results 
 
3.1. Behavioural experiments 
Exp1: 
IP GLP-1 infusion reduced FMS compared to vehicle significantly in sham rats 
(t (7) = 2.512, p = 0.04), but not in SDA rats (t (4) = -0.135, p = 0.899).  How-
ever, the comparison of the treatment differences (delta) between the two 
surgical groups did not reveal a significant difference (M = 1.988, SE = 0.79 in 
sham vs. M = -0.100, SE = 0.74 in SDA rats, respectively; t (11) = 1.789, p = 
0.101) (Fig. 1A). GLP-1 affected FMD compared to vehicle neither in sham 
animals (t (7) = 2.089, p = 0.75) nor in SDA animals (t (4) = -0.568, p = 0.60), 
and again there was no significant effect of the surgery on the treatment dif-
ferences (t (11) = 1.617, p = 0.134) (Fig. 1B). 
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Fig.1: IP infusion of 10 nmol/kg GLP-1 reduced first meal size in sham (t (7) = 2.512, p < 
0.05), but not in SDA rats. The comparison of the treatment differences (delta) between the 
two surgical groups did not differ significantly (A). The duration of the first meal was not sig-
nificantly affected by GLP-1 (B). Values are means ± SEM of 8 sham and 5 SDA rats. * p < 
0.05 vs. vehicle. 
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Exp2: 
There was a significant main effect of IP infused GLP-1 on FMS (F (3, 36) = 
9.162, p < 0.001).  Subsequent planned comparisons revealed a significant 
decrease in FMS after 30 and 90 nmol/kg.  The 10 nmol/kg dose appeared to 
reduce FMS compared to vehicle, but this difference did not reach statistical 
significance. Also, the reduction in FMS by GLP-1 was not significantly dose-
related, i.e., there were no significant differences between FMS after infusion 
of the 10 and 30 nmol/kg doses or the 30 and 90 nmol/kg doses, respectively 
(p > 0.05) (Fig. 2A).  Only the higher doses of GLP-1 (30 and 90 nmol/kg) re-
duced FMD compared to vehicle (F (3, 30) = 8.342, p < 0.001). Again no sig-
nificant dose-response relation could be detected (Fig. 2B). Thirty min after 
meal onset 30 and 90 nmol/kg GLP-1 significantly reduced CFI compared to 
vehicle infusion (F (3, 36) = 6.759, p < 0.01). After 60 min only the highest 
dose of GLP-1 (90 nmol/kg) decreased CFI significantly (F (3, 36) = 3.695, p < 
0.05).  After 120 and 180 min there was no significant main effect of the dif-
ferent treatments anymore (120 min: F (3, 39) = 2.335, p > 0.05; 180 min: F 
(3, 36) = 2.142, p > 0.05). At none of these time points a significant dose-
response relation could be shown (Fig. 2C). 
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Fig. 2: 30 and 90 nmol/kg of IP infused GLP-1 reduced first meal size (A) and duration (B). 
Values are means ± SEM. * p < 0.05 vs. vehicle, Bonferroni-Holm test after significant 
ANOVA. 
IP infusion of 90 nmol/kg GLP-1 reduced cumulative food intake 30 and 60 min after meal on-
set, 30 nmol/kg GLP-1 only after 30 min (C). Values are means ± SEM. * vehicle > 90 nmol/kg 
GLP-1, + vehicle > 30 nmol/kg GLP-1, p < 0.05, Bonferroni-Holm test after significant ANOVA. 
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3.2. C-Fos experiment 
In the hindbrain, IP injected GLP-1 increased the number of c-Fos positive 
cells only in the NTS at 14.0 mm posterior to bregma significantly (t (11) = -
2.348, p = 0.039), but not in the NTS at 13.5 (t (8) = 0.893, p = 0.398) and 
14.5 mm posterior (t (12) = -0.575, p = 0.576). The number of c-Fos positive 
cells was not increased in the AP either (t (6.3) = -1.564, p = 0.167). 
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Fig. 3: IP injection of 30 nmol/kg GLP-1 increased the number of c-Fos positive cells in the 
NTS at 14.0 mm posterior to bregma (t (11) = -2.348, p < 0.05) (B, D), but did not affect c-fos 
expression in the AP (E) or at other bregma levels in the NTS (A, C, D). Values are means ± 
SEM. * p < 0.05 vs. vehicle. 
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In the forebrain IP injected GLP-1 increased the number of c-Fos positive cells 
only in the caudal CeA significantly (t (9) = -2.431, p = 0.038). All other brain 
structures counted did not show a significant increase in c-fos expression 
(rostral CeA: t (13) = -0.284, p = 0.781; rostral Arc: t (13) = -1.021, p= 0.326; 
caudal Arc: t (11) = -0.888, p = 0.393; rostral PVN: t (6.6) = 0.316, p = 0.316; 
caudal PVN: t (8) = -2.018, p = 0.78). There seemed to be a tendency towards 
an increase in the caudal PVN, but this difference did not reach statistically 
significance. 
 
 
Fig. 4: IP injection of 30 nmol/kg GLP-1 induced c-fos expression in the caudal CeA (t (9) = -
2.431, p < 0.05) (F), not in any of the other regions in the forebrain (A-E). Values are means ± 
SEM. * p < 0.05 vs. vehicle. 
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Fig. 5: Representative examples of c-Fos staining in the NTS at 14.0 mm posterior to bregma 
in a vehicle (A) and a GLP-1 (B) treated rat and in the caudal part of the CeA in a vehicle (C) 
and a GLP-1 (D) treated rat.  
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4. Discussion 
 
4.1. Behavioural experiments 
In this study we investigated the effect of IP administered GLP-1 on food in-
take and whether this effect depends on intact abdominal vagal afferents. We 
detected a reduction in food intake in sham-operated rats after IP GLP-1 ap-
plication. It is noteworthy that we used a design which tried to mimic physio-
logical conditions as closely as possible, i.e., we administered a moderate 
dose of GLP-1 (10 nmol/kg) by remotely controlled, meal-contingent infusion. 
With a similarly low dose of IP administered GLP-1 so far only two studies 
could show an effect of GLP-1 on food intake (76;80), whereas others failed to 
see an effect or used higher doses (79;82;103). The two other positive studies 
in which 10 nmol/kg GLP-1 were administered used a design with ad libitum 
fed animals, whereas in the study that failed to reveal an effect of GLP-1 to 
reduce food intake at this dose, animals were food deprived for 24 h. For 
technical reasons we did also food deprive our rats, but only for the 12 h light 
phase, i.e. during the rats’ inactive phase, when food intake is much lower 
than during the dark, active phase of the circadian cycle. This food depriva-
tion, however, might explain our smaller effect (a reduction of food intake of 
about 30 % after GLP-1 administration) compared to the effect seen in the 
studies with ad libitum feeding (reduction of about 50 %). Indeed, the changes 
in metabolic state induced by prolonged fasting seem to affect the potency of 
GLP-1 to reduce food intake. Williams et al. showed that in their study the eat-
ing-inhibitory effect of 10 nmol/kg GLP-1 injected IP was gone when the ani-
mals were food deprived for 24 h prior to the injections (80). They hypothe-
sised that this may result from low plasma leptin levels induced by fasting, as 
leptin is supposed to interact with short-term satiation signals including GLP-1 
(80). Similar interactions with leptin were described for CCK (114), and also 
higher doses of CCK were necessary for a reduction in food intake when the 
animals were fasted for 48 h compared to 12 h (115). A recent study showed 
meal anticipatory GLP-1 secretion in meal-fed animals. Rats kept on a special 
feeding schedule (4 h/d access to food) had a GLP-1 plasma peak about 75 
min before the meal. Ad libitum fed rats did not reveal such an increase. This 
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pre-meal peak in GLP-1 may prepare the meal-fed animals for a large meal 
and therefore help them to better cope with this situation because GLP-1 re-
laxes the gastric fundus and increases stomach capacity (116). Taken to-
gether, GLP-1 administration after a scheduled food deprivation does not 
necessarily represent the ideal physiological setting for GLP-1’s satiating ef-
fect and may therefore account for its reduced effectiveness. 
Even though GLP-1 reduced food intake only in sham and not in SDA rats, we 
failed to show that the effect of GLP-1 was significantly different between sur-
gical groups. As mentioned above, Rüttimann et al. showed such a difference, 
but they used a slightly different setup with ad libitum fed rats, what could 
have contributed to their somewhat more pronounced effect compared to 
ours. Another study investigating the role of the vagus in GLP-1’s effect on 
eating used the less selective model of total subdiaphragmatic vagotomy and 
a dose of 100 nmol/kg GLP-1 injected IP after a 24 h food deprivation (82). In 
this study GLP-1 significantly reduced food intake in sham-vagotomised rats 
by about 20 %, whereas it did not significantly affect food intake in vagoto-
mised animals. The authors interpreted their findings as evidence for a role of 
the vagus in the eating-inhibitory effect of GLP-1, but they did not directly 
compare the differences in food intake between the two surgical groups as we 
did. Taken together, these results suggest that the inhibitory effect of IP ad-
ministered GLP-1 is mediated by vagal afferents. To get a clearer result our 
design should be optimised, i.e. the animals should have ad libitum access to 
food or the dose should be increased, as it is likely that our dose under our 
conditions was too low to reveal a clear surgical effect. 
 
In the second experiment (Exp2) we tested different doses of IP GLP-1 (10, 
30 and 90 nmol/kg) and found the two higher doses to be clearly effective to 
inhibit eating, whereas the 10 nmol/kg dose yielded only a tendency. Overall, 
these findings are consistent with the available literature (79;81;82;103), and 
minor discrepancies can presumably be explained by the different experimen-
tal designs used. Dakin et al. for instance failed to show a significant reduction 
of food intake with 30 nmol/kg GLP-1, but they had fasted their animals for 24 
h and injected the rats during the early light phase (79). We, in contrast, used 
a more sophisticated system of remotely controlled intrameal infusions and 
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performed the experiment at the beginning of dark phase. The fact that we 
found only a tendency towards a food intake reduction with the 10 nmol/kg 
dose of GLP-1 and could not replicate the significant eating-inhibitory effect 
that we observed with this dose in the first experiment (Exp1) again suggests 
that with our experimental design the threshold dose for an eating-inhibitory 
effect of GLP-1 is around 10 nmol/kg, i.e., this dose once revealed an effect 
and once not. 
 
We also tested whether the satiating effect of GLP-1 is dose-related and 
found a trend that did not reach statistical significance. Most studies examin-
ing the effect of IP applied GLP-1 in rats either used only one dose or did not 
critically test for dose-relationship (76;80;82;89;103). In mice, however, a 
dose-related effect of IP GLP-1 on eating was shown (103). After IV GLP-1 
some authors reported a dose-related effect of GLP-1 in rats (73;75), whereas 
others failed to demonstrate this (76). SC administration of the long-acting 
GLP-1 derivative NN2211 in rats (77) as well as IM injection of Ex4 in rhesus 
monkeys (83), however, inhibited eating in a dose-dependent manner. Yet, 
not all of these studies used stringent criteria for the definition of dose-
relationship and applied accordant statistics. Further explanations for the dis-
crepancies between different studies could be different routes of administra-
tion, different species or different experimental designs. Generally the effect of 
a substrate and whether it acts dose-dependently should depend on how 
many receptors are bound for how long. And indeed the studies that detected 
a dose-relationship worked with the GLP-1 receptor agonist Ex4 (83), which is 
not degraded by DPP-IV, with a long-acting GLP-1 derivative (77), or infused 
GLP-1 for a longer time (40 min to 3h) (73;75). 
 
In our experiment, CFI was not affected anymore after 60 min by 30 nmol/kg 
and after 120 min by 90 nmol/kg GLP-1, respectively. This finding that GLP-1 
had only a short-term eating-inhibitory effect and basically just reduced the 
size and duration of the first meal is consistent with previous reports (81;89) 
and can be explained by the short biological half-life of GLP-1 and its rapid 
degradation by DPP-IV. In contrast, Ex4, which is resistant to the degradation 
by DPP-IV, still affected CFI after 4 h (80). 
Discussion 
   31 
 
4.2. C-Fos experiment 
Here we studied c-fos expression in the fore- and hindbrain of rats after IP 
administration of GLP-1 using a dose that had been tested and shown to be 
effective in the behavioural study (Exp2). This is especially important, as there 
is evidence that the threshold for c-fos expression is generally higher than for 
behavioural effects (95;117). In our experiment IP injection of 30 nmol/kg 
GLP-1, a dose which clearly decreased food intake, was associated with an 
increase in the number of c-Fos positive cells in the caudomedial part of the 
NTS, but did not induce a significant increase in c-fos expression in the AP. 
Previous studies, investigating neuronal activation patterns in rats after IP 
administration of GLP-1, used smaller doses of GLP-1 (7.6 and 10 nmol/kg 
respectively) (100;103) or did not investigate c-fos expression in the hindbrain 
(82). One of these studies, using 7.6 nmol/kg GLP-1, did not test for behav-
ioural effects and failed to show an increased number of c-Fos positive cells in 
any region of the brain (100). Another report failed to demonstrate an increase 
in  c-fos expression after IP injection of 10 nmol/kg GLP-1, which had not af-
fected food intake either (103). Thus, these doses seem to be too low to trig-
ger an increase in c-fos expression, and such an increase could not have 
been expected (95;117), given the failure of GLP-1 to affect eating under 
comparable conditions (103). 
Vagal afferents project to the NTS (118), where the subdiaphragmatic vagal 
afferents are mainly represented in the caudomedial nucleus of the NTS 
(109). There is a viscerotopic organisation within the NTS, i.e. visceral affer-
ents terminate in  the caudomedial NTS, whereas the rostral NTS receives 
oropharyngeal inputs (119). Therefore, activation of the caudomedial NTS 
would be expected in response to abdominal vagal afferent signalling.  The 
results of our c-Fos experiment are consistent with this prediction and in line 
with the results from our behaviour study with SDA rats. Together these data 
support the hypothesis that the eating-inhibitory effect of IP injected GLP-1, 
unlike the effect of IV administered GLP-1, is mediated by vagal afferents 
(76). 
Infusion of GLP-1 into the HPV triggered a similar neuronal activation pattern 
in the caudal and medial parts of the NTS as IP injection did, but also acti-
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vated the AP (101). A major part of the IV administered GLP-1 is supposed to 
reach the brain via CVO, which are located on the peripheral side of the BBB, 
and the AP is one of these CVO. A study comparing IV (femoral vein) and ICV 
Ex4 administration showed a similar brain pattern of c-Fos positive cells after 
the two routes of administration apart from the AP, where IV Ex4 induced 
much more c-fos (53). This also suggests that IV GLP-1 and its receptor ago-
nist might act upon the brain via the AP, which contains GLP-1 receptors (34). 
The lack of a significant increase in c-fos expression in the AP after IP in-
jected GLP-1 is consistent with the fact that the AP does not seem to be cru-
cial for the hypophagic effect of peripheral GLP-1 receptor activation. A lesion 
study showed that rats with ablated AP responded similarly to IP injected Ex4 
as sham animals did. However, the AP lesioned animals showed attenuated 
c-fos expression in various brain areas, which implicates the AP in mediating 
the activation of CNS by GLP-1 (120). 
 
In the forebrain we only detected an increased number of c-Fos positive cells 
in the caudal part of the CeA, whereas c-fos expression did not differ between 
GLP-1 and vehicle treated animals in the PVN, the Arc and the rostral part of 
the CeA. 
Previous studies in rats using 7.6 and 10 nmol/kg IP injected GLP-1 did not 
find c-fos induction in the PVN or Arc (100;103). As mentioned above, these 
doses seem to be too low, as no increase in c-fos expression in any of the in-
vestigated brain areas could be detected. Another report showed an increase 
in c-Fos positive cells in the Arc after the administration of 100 nmol/kg (82). 
This is a much higher dose than ours, which could explain why these authors 
found an activation of the Arc. However, the possibility that the Arc was acti-
vated in relation to an effect of GLP-1 on glucose metabolism and not satia-
tion, can of course not be excluded, as other studies implicated the Arc in the 
incretin effect of GLP-1, whereas the PVN appears to modulate its satiation 
effect (72). 
One nmol/kg GLP-1 infused into the HPV also induced c-fos in the CeA, but 
not in the hypothalamus (Arc, PVN) (101). This activation pattern is consistent 
with our findings. As in our study, and related to the route of administration, a 
comparatively low dose was used, which still affected food intake under simi-
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lar conditions (101). In contrast, infusion of Ex4 into the femoral vein activated 
several brain areas including AP, NTS, PVN and Arc (53). This potent activa-
tion of c-fos expression can probably be explained by the rather strong and 
long-term receptor stimulation because unlike GLP-1, Ex4 is not degraded by 
DPP-IV. 
In sum, some authors report an increase in c-Fos positive cells in the hypo-
thalamus after GLP-1 or Ex4 administration in rats, whereas we failed to show 
such an effect. This discrepancy might be related to different doses, routes of 
administration or the use of the native hormone (GLP-1) vs. the synthetic re-
ceptor agonist (Ex4). However, we can not exclude that the hypothalamus 
was also somewhat activated under our conditions and that we just failed to 
detect a small increase in c-Fos positive cells with our technique. Moreover, 
since c-fos expression is induced by changes in signal transduction pathways 
and not by depolarisation per se (93), no c-Fos positive cells do not necessar-
ily mean no activation. 
 
NTS neurons project to the hypothalamus and other forebrain regions (121). 
The hypothalamus, in particular the PVN, the lateral (LH), dorsomedial (DMH) 
and ventromedial hypothalamus (VMH), is considered an integrative area for 
the control of eating (122). The amygdala receives inputs from the hypothala-
mus and is also involved in the control of ingestive behaviour (123). GLP-1 
receptors are present in different areas of the hypothalamus as well as in the 
amygdala (30;124). Injections of GLP-1 into the PVN (125;126), LH, DMH and 
VMH (127) reduced food intake, arguing for a role of the hypothalamus in me-
diating GLP-1 signals. In the Arc GLP-1 receptor-expressing neurons are 
highly co-localized with proopiomelanocortin (POMC), but not with neuropep-
tide Y (NPY) neurons (72), suggesting the GLP-1 effect to be mediated by the 
melanocortin system, which is involved in catabolic processes (1). 
Regarding our data, however, it should be considered that the results men-
tioned above are presumably more related to central GLP-1 and that there 
could be important differences between the actions of central and peripheral 
GLP-1, which we tried to mimic by IP administration. Thus, GLP-1 that is in-
jected directly into the brain and acts on central GLP-1 receptors may not elicit 
the same responses as IP injected GLP-1, which indirectly activates brain 
Discussion 
   34 
structures via neuronal projections. Therefore, peripheral GLP-1 does not 
necessarily have to induce c-fos expression in those brain regions shown to 
be activated by central GLP-1 administrations. 
 
Hayes et al. (70) further investigated the importance of the hypotha-
lamic/forebrain processing of GLP-1 signalling in chronic supracollicular de-
cerebrate (CD) rats. In these rats the neuraxis is completely transected to 
block forebrain-caudal brainstem communication. CD rats do not forage or ini-
tiate a meal by themselves and therefore food has to be delivered directly into 
their mouth. However, they respond similarly to IP administration of Ex4 as 
neurologically intact rats, and in both animal preparations Ex4 decreased glu-
cose intake, suggesting that caudal brainstem processing is sufficient for the 
behavioural response to IP GLP-1 receptor activation (70). Another study, 
however, reported no effect of IP injected GLP-1 on food intake in brainstem-
hypothalamic pathway transected rats, whereas the sham-transected rats re-
vealed such an effect (82). Even though the differences in food intake be-
tween the two surgical groups were not directly compared, the authors con-
cluded that the forebrain is indispensable for GLP-1’s inhibitory effect on food 
intake (82). The opposite results of these two studies are probably related to 
differences in the method and exact site of transection. A recent study claimed 
a major role of the hindbrain in GLP-1’s effect in the control of food intake, by 
showing that GLP-1 receptor blockage in the NTS increased food intake 
(128). Taken together, the hindbrain certainly plays an essential role in the 
mediation of GLP-1 signalling, whereas the forebrain, though important for in-
tegrating and further processing of these signals, is presumably less funda-
mental. 
 
The neuronal activation pattern that we found in the hindbrain after IP injection 
of GLP-1 is similar to that after consumption of a meal or satiation, respec-
tively (96-98). Some studies report an additional activation of the AP (94;95), 
which tends to result from larger meals. Hence, the c-fos expression in the 
hindbrain we report here is consistent with the assumption that the reduction 
of meal size after IP GLP-1 resembles satiation. 
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In the forebrain eating did not only activate the CeA, as we saw after IP GLP-1 
administration, but also induced c-fos expression in the PVN (97). This differ-
ence might be explained by the fact that eating to physiological satiation is 
certainly a much more complex process and includes many more signals than 
just GLP-1 and therefore most likely activates the brain to a larger extend. 
 
Regarding the fact that there are controversial reports concerning the question 
of whether the eating-inhibitory effect of GLP-1 is due to satiation or illness, it 
is interesting that we found activation of the CeA, but not of the hypothalamus. 
Several studies showed an association between CeA and visceral malaise 
(129-131), and various brain regions have been shown to be associated with 
either satiation or illness or both. 3rd ventricular ICV administration of GLP-1 
doses that led to a short-term reduction in food intake produced a conditioned 
taste aversion (CTA) (132), which is a common indicator for visceral illness in 
rodents. Another study reports that injection of GLP-1 into the lateral ventricle 
reduced food intake and supported a CTA, whereas 4th ventricular injection of 
GLP-1 only reduced food intake without causing CTA, and GLP-1 injection di-
rectly into the CeA induced CTA without causing anorexia (129). GLP-1 infu-
sion into the PVN suppressed food and water intake without leading to CTA 
(125). All in all, GLP-1 may therefore act in the hindbrain or in the PVN to re-
duce food intake, whereas an effect of GLP-1 in the CeA might be associated 
with nausea and illness. 
IP injected Ex4, in contrast, reduced food intake without inducing kaolin con-
sumption, which is another indicator for visceral illness (133). However, there 
are reports of humans experiencing mild to moderate nausea or emesis after 
SC treatment with the pharmaceutical Exenatide (Ex4), usually most promi-
nent in the first weeks of therapy and decreasing thereafter (134). 
Overall, whether GLP-1 induces an aversion or not seems to depend on the 
dose and route of administration. There is evidence that central GLP-1 is in-
volved in the mechanisms of visceral illness, at least under certain conditions 
(135). Based on this single report about IP Ex4 and kaolin intake (133) it ap-
pears unlikely that peripheral GLP-1 inhibits food intake because of visceral 
illness. However, we can not exclude the possibility that under certain condi-
tions a CTA is involved in the eating-inhibitory effect of peripheral GLP-1 in 
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rats and that the reduction of meal size that we found in our behavioural stud-
ies was due to visceral illness rather than satiation. Further investigations are 
needed to clarify this point; particularly useful would be a CTA test after pe-
ripheral application of GLP-1. 
 
4.3. Conclusions and perspectives 
The physiological site of action of intestinal GLP-1 to reduce food intake is still 
unclear. Our aim was therefore to investigate the signalling pathways (afferent 
nerves and brain networks) of IP administered GLP-1. In a first experiment 
(Exp1), a behaviour study using SDA rats, we found that the reduction of food 
intake after IP infused GLP-1 was attenuated by SDA. Furthermore, in the 
subsequent c-Fos study we saw that the NTS, the hindbrain region to which 
vagal afferents project (109), was activated after IP injection of GLP-1. Hence, 
we conclude that the eating-inhibitory effect of IP administered GLP-1 is me-
diated by vagal afferents. Interestingly, GLP-1 was shown to activate gastric 
vagal afferents in one study (136). Given the idea that endogenous GLP-1 
might have a paracrine effect on intestinal vagal afferents, further investiga-
tions of the role of the vagus nerve in the signalling pathway of GLP-1 should 
also include recordings from intestinal vagal afferents in response to GLP-1. 
In addition, it would be interesting to evaluate neuronal activation patterns of 
SDA rats after IP administration of GLP-1, the prediction being that SDA 
should prevent the neural activation seen after IP injection of GLP-1 in sham-
operated animals. 
We found not only an activation of the hindbrain after IP administration of 
GLP-1, but also some activation in the forebrain, possibly reflecting an in-
volvement of the forebrain in the presumably complex eating-inhibitory proc-
ess initiated by GLP-1. However, of course we do not know whether the acti-
vated brain areas are in fact involved in the behavioural response to GLP-1, 
and at present little is known about the hindbrain-forebrain communication 
and the neurotransmitters involved. There is evidence that serotonin (5-
hydroxytryptamin = 5HT) could be part of these mechanisms. A study compar-
ing the effect of IP GLP-1 on eating in 5HT2c receptor knockout and corre-
sponding wild-type mice found that GLP-1 failed to decrease food intake in the 
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5HT2c receptor knockout mice (104). As it seems that 5HT signalling via 
5HT2c receptors is required for the satiation response of GLP-1, it would be 
interesting to evaluate c-fos expression in response to IP GLP-1 in the mid-
brain raphe area, where a high density of serotonergic neurons is present 
(137). A subsequent double labelling study after GLP-1 administration would 
further illuminate a possible co-localization of c-fos expressing and serotoner-
gic neurons. 
 
Given the intriguing parallels between GLP-1 and CCK, such as the origin of 
both peptides in the gut (5;39), their role in satiation (16;76) as well as the 
evidence for their paracrine effects involving mediation by vagal afferent sig-
nalling (11;76;82), it is interesting to compare c-fos expression in the brain af-
ter administration of CCK and GLP-1. In the brainstem IP administration of 
CCK activated rostral as well as caudal parts of the NTS (96;99;138;139) and 
this increase in c-Fos positive cells was dose-dependent (98). The activation 
of the NTS after CCK application is once again consistent with the well- 
documented dependence of CCK’s satiating effect on intact vagal afferents 
(107;108). Some authors also observed an increased c-fos expression in the 
AP after IP CCK (98;99;139), whereas others did not (96). Activation of the AP 
after CCK application seems to depend on the dose, with high doses having 
an effect (98). In the forebrain, neuronal activation of the PVN as well as of 
the CeA was reported after IP CCK injection (99;138;140). Taken together, 
the neuronal activation pattern after IP CCK administration is somehow similar 
to what we observed after GLP-1 injection, but overall the reports are also 
rather inhomogeneous depending on doses and designs used. 
 
We also compared our results with IP injected GLP-1 to the neuronal activa-
tion after IV administered GLP-1, regarding the hypothesis that GLP-1 may 
recruit different neural pathways to inhibit eating after IP or HPV administra-
tion (76). Our findings support this hypothesis and we therefore propose a 
model that the satiating effect of IP injected GLP-1 is mediated by the vagus 
and that in this situation GLP-1 first activates the NTS from where the signal 
propagates to forebrain structures, whereas IV administered GLP-1 reaches 
the brain via the circulation and acts in the AP to further activate the NTS and 
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other brain regions (76;101). To further clarify the role of the AP in the eating-
inhibitory response of IV GLP-1, lesion studies might be helpful because ac-
cording to this model, AP lesions should block the eating-inhibitory effect of 
IV, but not IP administered GLP-1. 
For several reasons (see introduction) we consider IP administration of GLP-1 
to better mimic physiological conditions than IV administration. However, pe-
ripheral GLP-1 is physiologically secreted by mucosal L-cells of the intestinal 
wall. Therefore, another interesting possibility to approximate physiological 
conditions would be to perform further experiments to determine the effects of 
intraintestinally administered GLP-1 on food intake and c-fos expression and 
their dependence on the vagus. Such an approach would of course require 
that the administered GLP-1 is protected from proteolytic degradation in the 
lumen. 
A synergism of GLP-1 and glucose to stimulate insulin release was shown 
and for this incretin effect of GLP-1 a vago-vagal reflex loop originating in the 
hepatoportal system was proposed (141). Thus, given the fact that GLP-1 
specifically reduces meal size in situations when circulating glucose concen-
tration supposedly increases, a similar GLP-1-glucose synergism might also 
contribute to the satiation effect of GLP-1. Further studies are warranted to 
investigate this possibility. 
 
In general, the physiological role of endogenous peripheral GLP-1 in satiation 
is controversially discussed, as for instance the results after administration of 
GLP-1 receptor antagonists are inconsistent (81;89). The missing dose-
relationship in our experiment also argues against physiological relevance of 
GLP-1 in the graded satiation effect of food intake (142). It might however well 
be that endogenous peripheral GLP-1 has only a permissive effect and, 
hence, can contribute to meal termination together with other factors, but that 
it is not necessarily required for physiological satiation. 
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6. Abbreviations 
 
Arc   arcuate nucleus of the hypothalamus 
AP  area postrema 
BBB  blood brain barrier 
BW  body weight 
CCK  cholecystokinin 
CD  decerebrate rats 
CeA  central nucleus of the amygdala 
CFI  cumulative food intake 
CNS  central nervous system 
CTA  conditioned taste aversion 
CVO  circumventricular organs 
DPP-IV dipeptidyl peptidase IV 
DMH  dorsomedial hypothalamus 
DMX  dorsal motor nucleus of the vagus 
Ex4  exendin-4 
Ex9  exendin (9-39) 
FMD  first meal duration 
FMS  first meal size 
GIP  glucose-dependent insulinotropic polypeptide 
GIT  gastrointestinal tract 
GLP-1  glucagon-like peptide-1 
HPV  hepatic portal vein 
ICV  intracerebroventricular 
IHC  immunohistochemistry 
IM  intramuscular 
IP  intraperitoneal 
IV  intravenous 
LH  lateral hypothalamus 
NTS  nucleus tractus solitarii 
PVN  paraventricular nucleus of the hypothalamus 
PYY  peptide YY 
Abbreviations 
   52 
ROI  regions of interest 
SC  subcutaneous  
SDA  subdiaphragmatic vagal deafferentation 
VC  vena cava 
VMH  ventromedial hypothalamus 
5HT  5-hydroxytryptamin = serotonin 
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